Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective May 4, 2026.

Back to dashboard

Medicare AdvantageAdministrativeMedium impact

MA08.156d, Teclistamab-cqyv (Tecvayli®)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

May 4, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.156d for Teclistamab-cqyv (Tecvayli®) has been updated with medical coding, general description, guidelines, or informational changes. This is a pharmacy policy update that may affect billing procedures for this specialized oncology medication.

Action Required

Action needed

By May 4, 2026: Billing team should review the updated policy MA08.156d for Teclistamab-cqyv (Tecvayli®) at the provided URL to understand any changes to medical coding guidelines, coverage criteria, or billing procedures for this oncology medication. Update billing protocols and staff training as needed based on the specific policy changes.

Related policy hubs

Independence Blue Cross policies Oncology Hematology